- Report
- May 2024
- 139 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 138 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 132 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 132 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 136 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 139 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 135 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- August 2022
- 119 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- September 2023
- 160 Pages
Global
From €3224EUR$3,599USD£2,748GBP
- Report
- January 2024
- 200 Pages
Global
From €3717EUR$4,150USD£3,169GBP
- Report
- August 2023
- 56 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- November 2023
- 113 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- June 2022
- 320 Pages
Global
From €12450EUR$13,900USD£10,613GBP
- Report
- January 2024
- 120 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Report
- January 2022
- 150 Pages
Global
From €1344EUR$1,500USD£1,145GBP
- Report
- May 2021
- 250 Pages
Global
From €8016EUR$8,950USD£6,834GBP
- Report
- September 2024
- 80 Pages
Japan
From €2665EUR$2,975USD£2,271GBP
€3135EUR$3,500USD£2,672GBP
- Report
- January 2024
- 174 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Report
- January 2024
- 171 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- February 2024
- 131 Pages
Global
From €4255EUR$4,750USD£3,627GBP

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more